secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001104659-25-075944
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics reports Q2 2025: VCN-01 Phase 2b success, cash $12.1M, runway into Q1 2026
--------------------------------------------------------------------------------

- Positive topline from VIRAGE Phase 2b: VCN-01 plus chemo improved OS, PFS, DOR vs chemo alone in metastatic pancreatic cancer.
- Cash and cash equivalents $12.1M as of June 30, 2025; early Aug cash $9.5M, expected runway into Q1 2026.
- G&A expenses $11.2M (up 662% YoY) due to $9.2M contingent consideration adjustment from VIRAGE success; R&D $2.0M (down 34%).
- Expanded VIRAGE data to be presented at ESMO 2025 Congress in October.
- Phase 1 retinoblastoma data of VCN-01 presented at ASCO 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925075944/0001104659-25-075944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925075944/tm2522967d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-075944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer